Robert Mark Weisskoff

Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH.

Topaz Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on developing and commercializing treatments for the pediatric and dermatology markets. Its lead investigational product is a topical cream formulation of ivermectin which is under development. The firm provides medicines for the treatment of head lice, acne and infections, as well as vaccines against childhood diseases. The company was founded by Donald P. Beeman and Nicholas U. Spring in 2005 and is headquartered in Horsham, PA.

Bioconnect Systems, Inc. provides surgical implants and techniques that form controlled vascular connections. It offers Optiflow, a family of anastomotic connectors that provides repeatable method for connecting vessels. The company was founded by Michael Dugery and Adam D. Dakin on May 8, 2006 and is headquartered in Ambler, PA.

Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.

TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA.

Farapulse, Inc. engages in the development of medical devices. Its products are: Endo Farawave, a percutaneous catheter designed to create transmural and contiguous lesions on the endocardium of the left atrium to isolate the pulmonary veins and EPI Faraone, s designed to create a box lesion around all pulmonary veins from an epicardial placement of the catheter for the treatment of atrial fibrillation. The company was founded by Steven Mickelsen in 2014 and is headquartered in Iowa City, IA.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals.

The Phi Beta Kappa Society operates as an organization for liberal arts and science education. The non-profit company is based in Washington.

Trivitron Healthcare Pvt Ltd. manufactures and distributes medical equipment. Its products include virtual dissection table, newborn screening, ultrasound, ventilators, electrophoresis, and histopathology. The company was founded by Gomathi Babu Sadacharam Kulandai Velu in 1997 and is headquartered in Chennai, India.

RareCyte Inc. develops life science research and diagnostic that focuses on characterizing and isolating rare cells in the blood. It engages in bringing its technology to the life sciences research, drug development and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. It's ground-breaking sccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. The company was founded by Ronald Seubert in 2009 and is headquartered in Seattle, WA.

XCyton Diagnostics Pvt Ltd. operates as a molecular biology company which provides diagnostic products. It offers syndrome evaluation system which allows the simultaneous identification of multiple organisms inclusive of bacteria, viruses, fungi and parasites, in a specific test from a single sample. The firm also develops immunodiagnostic kits for the detection of infections. The company was founded by Venkata Ravi Kumar Banda on September 30, 1993 and is headquartered in Bangalore, India.

Core Diagnostics Pvt Ltd. provides diagnostics for disease stratification and therapy selection. It provides services such as second opinion, customized report, unique tests and doorstep service. The company was founded by Arghya Basu and Zoya Brar and is headquartered in Gurgaon, India.

Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston.

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

Zenflow, Inc. provides medical services. The firm provides solutions for urinary obstruction without destroying tissues. The company was founded by Nick Damiano and Shreya Mehta in 2014 and is headquartered in South San Francisco, CA.

PlasmaGen Biosciences Pvt Ltd. manufactures and sells pharmaceutical products for plasma protein therapy. It offers PlasmaGlob, AlbuMax, PlasmaRho-D I.V., PlasmaRho-I.M., PlasmaRAB, PlasmaHep, VerBumin, and Gammafact-VIII. The company was founded by Vinod Nahar on September 7, 2010 and is headquartered in Bangalore, India.

Part of Structure Therapeutics, Inc., Basecamp Bio USA, Inc. operates as a biotechnology company. The private company is based in South San Francisco, CA. The CEO of the company is Raymond Stevens.